


26 November 2019

ASX Code: MXC

## MGC Pharma growth in Prescriptions issued continues for its Cannabinoid Medicines during November

**MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company')**, a European based 'Seed to Medicine' bio-pharma company specialising in the production and development of phytocannabinoid derived medicines, is pleased to announce that it has seen the number of prescribed standardised, affordable cannabinoid medicines pass the 1,400 mark in Australia, the United Kingdom and recently Brazil through MGC Pharma's distributor ONIX Empreendimentos. This is a 40% growth since the end of October 2019.

ASX  
RELEASE



### Key Highlights:

- Prescriptions have increased 40% from 1,000 at the end of October 2019 to pass 1,400 as at 25 November 2019
- Unique patient numbers have increased 28% in the period since 31 October 2019
- An increasing number of return patients for MGC Pharma products is being seen, contributing to the prescription growth rate
- Further demonstrating the near-term revenue generating potential of the Company based on its phytocannabinoid derived medicines to patients in Australia, the U.K and now with access to Brazil and key Latin American markets
- Average Prescription orders are currently at 22 per business day

**Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented:** "We are delighted with continued momentum behind the business which is demonstrated by the ongoing growth in the number of prescriptions, increasing by 40% since the end of October, with an increasing number of return patients. This shows the near-term revenue generating potential of the Company based on its phytocannabinoid derived medicines which are now available to patients in Australia, the U.K and Brazil under early access schemes. We look forward to updating the market on our further progress as we approach the New Year."

## Further Information

MGC Pharma is pleased to have passed a further target as an emerging bio-pharma company during November, with prescriptions for its phytocannabinoid derived medicines reaching over 1,400 across Australia, UK and recently with first prescriptions issued in Brazil, demonstrating its strengthening position in each market. This growth is seen to accentuate from patients returning for repeat orders. In addition, a number of other patients are being treated with MGC Pharma products globally via participation in ongoing clinical research. The commercialisation of its portfolio of phytocannabinoid derived medicines is in line with its strategy of becoming a world-leading bio-pharma company through international distribution agreements.

CannEpi<sup>®</sup> and MXP100 are both proprietary MGC Pharma products that have been developed internally through the Company's Research and Development division and progressed through to commercialisation. This is in line with the Company's 'Seed to Medicine' strategy with the Company owning all the intellectual property through each stage of a product's development, from the genetics to finished pharmaceutical grade product.

The Company continues to work closely with its designated distributors to onboard further clinics, in addition to independent medical professionals, in each region increasing patient access to its phytocannabinoid derived medicines under the relevant legislation in each jurisdiction.

--Ends--

### For further information, please contact:

#### UK IR/Media Advisors

Catherine Leftley/Megan Dennison  
St Brides Partners Ltd  
+44 (0) 207 236 1177  
[megan@stbridespartners.co.uk](mailto:megan@stbridespartners.co.uk)  
[catherine@stbridespartners.co.uk](mailto:catherine@stbridespartners.co.uk)

#### MGC Pharmaceuticals Ltd

Brett Mitchell  
Executive Chairman  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is a European based bio-pharma company supplying phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting three widespread medical conditions - epilepsy, dementia and IBS – and has further products in the development pipeline.

Employing its 'Seed to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and recent research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana, highlighted the positive impact of using specific phytocannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia and the UK and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. In order to meet the demands of becoming a key global supplier the company is constructing a 15,720m<sup>2</sup> GMP state of the art facility in Malta.

Follow us through our social media channels    